Skip to main content
SpringerLink
Log in
Book cover

Severe Fever with Thrombocytopenia Syndrome pp 185–196Cite as

Antiviral Drugs for the Therapeutics of SFTS

  • Chapter
  • First Online:

  • 381 Accesses

Abstract

Severe fever with thrombocytopenia syndrome (SFTS) virus (SFTSV) is the causative agent of SFTS. Despite the medical importance of this disease, there are currently neither vaccines nor effective therapeutics for SFTS. Ribavirin has been an effective antiviral drug against several RNA virus infections. Favipiravir, which is a pyrazine derivative, has also shown broad antiviral activity against various RNA viruses. In this chapter, characteristics of ribavirin and favipiravir in viral infection and their antiviral effects in the treatment of SFTSV infections in vivo are described.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Baba M, Toyama M, Sakakibara N, Okamoto M, Arima N, Saijo M (2017) Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitors. Antivir Chem Chemother 25:83–89

    Article  Google Scholar 

  • Bai CQ, Mu JS, Kargbo D, Song YB, Niu WK, Nie WM, Kanu A, Liu WW, Wang YP, Dafae F, Yan T, Hu Y, Deng YQ, Lu HJ, Yang F, Zhang XG, Sun Y, Cao YX, Su HX, Sun Y, Liu WS, Wang CY, Qian J, Liu L, Wang H, Tong YG, Liu ZY, Chen YS, Wang HQ, Kargbo B, Gao GF, Jiang JF (2016) Clinical and virological characteristics of ebola virus disease patients treated with favipiravir (T-705)-Sierra Leone, 2014. Clin Infect Dis 63:1288–1294

    Article  Google Scholar 

  • Bougie I, Bisaillon M (2004) The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme. J Biol Chem 279:22124–22130

    Article  CAS  Google Scholar 

  • Carrillo-Bustamante P, Nguyen THT, Oestereich L, Gunther S, Guedj J, Graw F (2017) Determining Ribavirin’s mechanism of action against Lassa virus infection. Sci Rep 7:11693

    Article  Google Scholar 

  • Chen XP, Cong ML, Li MH, Kang YJ, Feng YM, Plyusnin A, Xu J, Zhang YZ (2012) Infection and pathogenesis of Huaiyangshan virus (a novel tick-borne bunyavirus) in laboratory rodents. J Gen Virol 93:1288–1293

    Article  CAS  Google Scholar 

  • Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE (2000) The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 6:1375–1379

    Article  CAS  Google Scholar 

  • Ferm VH, Willhite C, Kilham L (1978) Teratogenic effects of ribavirin on hamster and rat embryos. Teratology 17:93–101

    Article  CAS  Google Scholar 

  • Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K (2002) In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46:977–981

    Article  CAS  Google Scholar 

  • Gowen BB, Westover JB, Sefing EJ, Van Wettere AJ, Bailey KW, Wandersee L, Komeno T, Furuta Y (2017) Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy. Antivir Res 145:131–135

    Article  CAS  Google Scholar 

  • Kamiyama N, Soma R, Hidano S, Watanabe K, Umekita H, Fukuda C, Noguchi K, Gendo Y, Ozaki T, Sonoda A, Sachi N, Runtuwene LR, Miura Y, Matsubara E, Tajima S, Takasaki T, Eshita Y, Kobayashi T (2017) Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremia in ZIKV-infected STAT1-deficient mice. Antivir Res 146:1–11

    Article  CAS  Google Scholar 

  • Kochhar DM, Penner JD, Knudsen TB (1980) Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice. Toxicol Appl Pharmacol 52:99–112

    Article  CAS  Google Scholar 

  • Liu Y, Wu B, Paessler S, Walker DH, Tesh RB, Yu XJ (2014) The pathogenesis of severe fever with thrombocytopenia syndrome virus infection in alpha/beta interferon knockout mice: insights into the pathologic mechanisms of a new viral hemorrhagic fever. J Virol 88:1781–1786

    Article  Google Scholar 

  • Lu QB, Zhang SY, Cui N, Hu JG, Fan YD, Guo CT, Qin SL, Yang ZD, Wang LY, Wang HY, Zhang XA, Liu W, Cao WC (2015) Common adverse events associated with ribavirin therapy for severe fever with thrombocytopenia syndrome. Antivir Res 119:19–22

    Article  CAS  Google Scholar 

  • McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R (1986) Lassa fever. Effective therapy with ribavirin. N Engl J Med 314:20–26

    Article  CAS  Google Scholar 

  • McKee KT Jr, Huggins JW, Trahan CJ, Mahlandt BG (1988) Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever. Antimicrob Agents Chemother 32:1304–1309

    Article  CAS  Google Scholar 

  • Oestereich L, Rieger T, Neumann M, Bernreuther C, Lehmann M, Krasemann S, Wurr S, Emmerich P, de Lamballerie X, Olschlager S, Gunther S (2014a) Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl Trop Dis 8:e2804

    Article  Google Scholar 

  • Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gunther S (2014b) Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antivir Res 105:17–21

    Article  CAS  Google Scholar 

  • Oestereich L, Rieger T, Ludtke A, Ruibal P, Wurr S, Pallasch E, Bockholt S, Krasemann S, Munoz-Fontela C, Gunther S (2016) Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever. J Infect Dis 213:934–938

    Article  CAS  Google Scholar 

  • Oh WS, Heo ST, Kim SH, Choi WJ, Han MG, Kim JY (2014) Plasma exchange and ribavirin for rapidly progressive severe fever with thrombocytopenia syndrome. Int J Infect Dis 18:84–86

    Article  CAS  Google Scholar 

  • Park I, Kim HI, Kwon KT (2017) Two treatment cases of severe fever and thrombocytopenia syndrome with oral ribavirin and plasma exchange. Infect Chemother 49:72–77

    Article  Google Scholar 

  • Rattanaburee T, Junking M, Panya A, Sawasdee N, Songprakhon P, Suttitheptumrong A, Limjindaporn T, Haegeman G, Yenchitsomanus PT (2015) Inhibition of dengue virus production and cytokine/chemokine expression by ribavirin and compound A. Antivir Res 124:83–92

    Article  CAS  Google Scholar 

  • Scharton D, Bailey KW, Vest Z, Westover JB, Kumaki Y, Van Wettere A, Furuta Y, Gowen BB (2014) Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antivir Res 104:84–92

    Article  CAS  Google Scholar 

  • Shimada S, Posadas-Herrera G, Aoki K, Morita K, Hayasaka D (2015) Therapeutic effect of post-exposure treatment with antiserum on severe fever with thrombocytopenia syndrome (SFTS) in a mouse model of SFTS virus infection. Virology 482:19–27

    Article  CAS  Google Scholar 

  • Shimojima M, Fukushi S, Tani H, Yoshikawa T, Fukuma A, Taniguchi S, Suda Y, Maeda K, Takahashi T, Morikawa S, Saijo M (2014) Effects of ribavirin on severe fever with thrombocytopenia syndrome virus in vitro. Jpn J Infect Dis 67:423–427

    Article  CAS  Google Scholar 

  • Shimojima M, Fukushi S, Tani H, Taniguchi S, Fukuma A, Saijo M (2015) Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection. Virol J 12:181

    Article  Google Scholar 

  • Sissoko D, Laouenan C, Folkesson E, M’Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V, Doumbouya L, Souley H, Kighoma PM, Koundouno FR, Rene L, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C et al (2016) Experimental treatment with favipiravir for ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med 13:e1001967

    Article  Google Scholar 

  • Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS (2014) Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antivir Res 104:153–155

    Article  CAS  Google Scholar 

  • Tam RC, Lau JY, Hong Z (2001) Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother 12:261–272

    Article  CAS  Google Scholar 

  • Tani H, Fukuma A, Fukushi S, Taniguchi S, Yoshikawa T, Iwata-Yoshikawa N, Sato Y, Suzuki T, Nagata N, Hasegawa H, Kawai Y, Uda A, Morikawa S, Shimojima M, Watanabe H, Saijo M (2016) Efficacy of T-705 (Favipiravir) in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus. mSphere 1:e00061-15

    Google Scholar 

  • Westover JB, Sefing EJ, Bailey KW, Van Wettere AJ, Jung KH, Dagley A, Wandersee L, Downs B, Smee DF, Furuta Y, Bray M, Gowen BB (2016) Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antivir Res 126:62–68

    Article  CAS  Google Scholar 

  • Yoshikawa T, Fukushi S, Tani H, Fukuma A, Taniguchi S, Toda S, Shimazu Y, Yano K, Morimitsu T, Ando K, Yoshikawa A, Kan M, Kato N, Motoya T, Kuzuguchi T, Nishino Y, Osako H, Yumisashi T, Kida K, Suzuki F, Takimoto H, Kitamoto H, Maeda K, Takahashi T, Yamagishi T, Oishi K, Morikawa S, Saijo M, Shimojima M (2014) Sensitive and specific PCR systems for detection of both Chinese and Japanese severe fever with thrombocytopenia syndrome virus strains and prediction of patient survival based on viral load. J Clin Microbiol 52:3325–3333

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Virology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan

    Hideki Tani

  2. Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan

    Hideki Tani & Masayuki Saijo

Authors
  1. Hideki Tani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masayuki Saijo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideki Tani .

Editor information

Editors and Affiliations

  1. Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan

    Masayuki Saijo

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tani, H., Saijo, M. (2019). Antiviral Drugs for the Therapeutics of SFTS. In: Saijo, M. (eds) Severe Fever with Thrombocytopenia Syndrome. Springer, Singapore. https://doi.org/10.1007/978-981-13-9562-8_15

Download citation

Publish with us

Policies and ethics

Search

Navigation